Nonclinical Safety Biomarkers of Drug-induced Vascular Injury: Current Status and Blueprint for the Future
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Better biomarkers are needed to identify, characterize, and/or monitor drug-induced vascular injury (DIVI) in nonclinical species and patients. The Predictive Safety Testing Consortium (PSTC), a precompetitive collaboration of pharmaceutical companies and the U.S. Food and Drug Administration (FDA), formed the Vascular Injury Working Group (VIWG) to develop and qualify translatable biomarkers of DIVI. The VIWG focused its research on acute DIVI because early detection for clinical and nonclinical safety monitoring is desirable. The VIWG developed a strategy based on the premise that biomarkers of DIVI in rat would be translatable to humans due to the morphologic similarity of vascular injury between species regardless of mechanism. The histomorphologic lexicon for DIVI in rat defines degenerative and adaptive findings of the vascular endothelium and smooth muscles, and characterizes inflammatory components. We describe the mechanisms of these changes and their associations with candidate biomarkers for which advanced analytical method validation was completed. Further development is recommended for circulating microRNAs, endothelial microparticles, and imaging techniques. Recommendations for sample collection and processing, analytical methods, and confirmation of target localization using immunohistochemistry and in situ hybridization are described. The methods described are anticipated to aid in the identification and qualification of translational biomarkers for DIVI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endothelial Function and Dysfunction: Testing and Clinical Relevance
Deanfield, J. E., Halcox, J. P., & Rabelink, T. J. (2007) · Circulation · doi:10.1161/circulationaha.106.652859 · Cited by 2,710
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Mehta, P. K., & Griendling, K. K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00287.2006 · Cited by 1,924
Pervasive roles of microRNAs in cardiovascular biology
Small, E. M., & Olson, E. N. (2011) · Nature · doi:10.1038/nature09783 · Cited by 1,180 · cited 1×
“They have been described as regulators of key signaling pathways involved in vascular and cardiovascular biology (Small and Olson 2011; Di Stefano et al. 2011; Fish and Cybulsky 2012; Hartmann and Thum 2011; Santoro 2011; Urbich, Kuehbacher, and Dimmeler 2008) and pathologic response, to include regulation of inducibl…”
BackgroundA microRNA array reveals extensive regulation of microRNAs during brain development
KRICHEVSKY, A. M., KING, K. S., DONAHUE, C. P., KHRAPKO, K., & KOSIK, K. S. (2003) · RNA · doi:10.1261/rna.5980303 · Cited by 1,040 · cited 1×
“MicroRNAs are small noncoding RNAs that regulate gene expression and play critical roles in many biological and pathological processes (Mikaelian et al. 2012; Chen et al. 2008; Baehrecke 2003; He et al. 2009; Krichevsky et al. 2003).”
BackgroundExport of microRNAs and microRNA-protective protein by mammalian cells
Wang, K., Zhang, S., Weber, J., Baxter, D., & Galas, D. J. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq601 · Cited by 1,002
Role of microRNAs in vascular diseases, inflammation, and angiogenesis
Urbich, C., Kuehbacher, A., & Dimmeler, S. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn156 · Cited by 880
Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease
Corsten, M. F., Dennert, R., Jochems, S., Kuznetsova, T., Devaux, Y., Hofstra, L., Wagner, D. R., Staessen, J. A., Heymans, S., & Schroen, B. (2010) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.110.957415 · Cited by 794
Caporali, A., Meloni, M., Völlenkle, C., Bonci, D., Sala-Newby, G. B., Addis, R., Spinetti, G., Losa, S., Masson, R., Baker, A. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.952325 · Cited by 397
Laverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., Holloway, C., McMahon, N., Milligan, J., Park, B., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01255.x · Cited by 363
Katare, R., Riu, F., Mitchell, K., Gubernator, M., Campagnolo, P., Cui, Y., Fortunato, O., Avolio, E., Cesselli, D., Beltrami, A. P., et al. (2011) · Circulation Research · doi:10.1161/circresaha.111.251546 · Cited by 344 · cited 1×
“2009); EC activation via the NF B signal transduction pathway (Fish and Cybulsky 2012); antiproliferative/antiangiogenic signaling via attenuation of eNOS expression (Chan et al. 2012; Chan et al. 2009; Katare et al. 2011; Liu et al. 2010a; Rippe et al. 2012); and control of arterial vascular tone through a paracrine…”
Background
Cited by
Human vascular microphysiological system for in vitro drug screening
Fernandez, C. E., Yen, R. W., Perez, S. M., Bedell, H. W., Povsic, T. J., Reichert, W. M., & Truskey, G. A. (2016) · Scientific Reports · doi:10.1038/srep21579 · Cited by 93
Frazier, K. S., Engelhardt, J. A., Fant, P., Guionaud, S., Henry, S. P., Leach, M. W., Louden, C., Scicchitano, M. S., Weaver, J. L., & Zabka, T. S. (2015) · Toxicologic Pathology · doi:10.1177/0192623315570340 · Cited by 35
“The search for DIVI markers has been formalized, with the formation of a collaborative consortium of industry, academic, and regulatory experts into The Predictive Safety Testing Consortium (PSTC) Vascular Injury Working Group (VIWG), and a panel of biomarkers for DIVI has been proposed (Mikaelian et al. 2014).”
BackgroundInfluentialSelf-citationSpecies differences in renal development and associated developmental nephrotoxicity
Frazier, K. S. (2017) · Birth Defects Research · doi:10.1002/bdr2.1088 · Cited by 35
Metadata
- Authors
- Mikaelian, I., Cameron, M., Dalmas, D. A., Enerson, B. E., Gonzalez, R. J., Guionaud, S., Hoffmann, P. K., King, N. M. P., Lawton, M. P., Scicchitano, M. S., Smith, H. W., Thomas, R. A., Weaver, J. L., Zabka, T. S., & The Vascular Injury Working Group of the Predictive Safety Consortium
- Venue
- Toxicologic Pathology
- Publisher
- SAGE Publications
- Published
- 2014-04-28
- Volume
- 42
- Issue
- 4
- Pages
- 635-657
- ISSN
- 0192-6233 (ISSN-L)
- 1533-1601
- OpenAlex
- W2170549192
- Cited by
- 46
- References
- 12
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nonclinical Safety Biomarkers of Drug-induced Vascular Injury: Current Status and Blueprint for the Future. https://app.cochat.ai/papers/10.1177/0192623314525686
- The paper
- Mikaelian, I., Cameron, M., Dalmas, D. A., Enerson, B. E., Gonzalez, R. J., Guionaud, S., Hoffmann, P. K., King, N. M. P., Lawton, M. P., Scicchitano, M. S., Smith, H. W., Thomas, R. A., Weaver, J. L., Zabka, T. S., & The Vascular Injury Working Group of the Predictive Safety Consortium. (2014). Nonclinical Safety Biomarkers of Drug-induced Vascular Injury: Current Status and Blueprint for the Future. Toxicologic Pathology. https://doi.org/10.1177/0192623314525686
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.